Paul Shabram

1.2k total citations
21 papers, 1.0k citations indexed

About

Paul Shabram is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Paul Shabram has authored 21 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Genetics and 6 papers in Oncology. Recurrent topics in Paul Shabram's work include Virus-based gene therapy research (9 papers), CAR-T cell therapy research (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Paul Shabram is often cited by papers focused on Virus-based gene therapy research (9 papers), CAR-T cell therapy research (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Paul Shabram collaborates with scholars based in United States, India and Canada. Paul Shabram's co-authors include Estuardo Aguilar-Córdova, Barry J. Sugarman, G W Demers, Bernard Huyghe, Mark Horn, Suganto Sutjipto, Murali Ramachandra, Wei Li, Cassandra Nyberg-Hoffman and Duane E. Johnson and has published in prestigious journals such as Nature Medicine, Nature Biotechnology and Gastroenterology.

In The Last Decade

Paul Shabram

19 papers receiving 893 citations

Peers

Paul Shabram

GENET

ONCOL

BIOTE

Frits J. Fallaux Netherlands

Mark A. Currier United States

Sari Pesonen Finland

Ronald R. Reichel United States

Dong‐Soo Im South Korea

Josephine N. Harada United States

Hédi Haddada France

T von Rüden Austria

B.C. Trapnell United States

Kenneth Rogulski United States

Frits J. Fallaux Netherlands

Paul Shabram

825 ×1.1

935 ×1.6

GENET

379 ×1.2

ONCOL

220 ×1.4

96 ×1.0

BIOTE

Citations per year, relative to Paul Shabram Paul Shabram (= 1×) peers Frits J. Fallaux

Countries citing papers authored by Paul Shabram

Since Specialization

Citations

This map shows the geographic impact of Paul Shabram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Shabram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Shabram more than expected).

Fields of papers citing papers by Paul Shabram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Shabram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Shabram. The network helps show where Paul Shabram may publish in the future.

Co-authorship network of co-authors of Paul Shabram

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Shabram. A scholar is included among the top collaborators of Paul Shabram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Shabram. Paul Shabram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Döll, W, Erik P. Sandefer, Richard C. Page, et al.. (2024). Su1778 RESULTS OF HUMAN DEVICE FUNCTION STUDIES FOR THE NAVICAP™ TARGETED ORAL DELIVERY PLATFORM IN HEALTHY VOLUNTEERS AND PATIENTS WITH UC. Gastroenterology. 166(5). S–809. 1 indexed citations

Feagan, Brian G., et al.. (2024). S1370 Single Ascending Dose Results From a Phase 1 Clinical Trial of BT-600, a Combination Product of the NaviCap Targeted Oral Delivery Platform and Tofacitinib. The American Journal of Gastroenterology. 119(10S). S978–S978. 1 indexed citations

Beaty, Shannon M., Nicos Karasavvas, Robert A. Kuschner, et al.. (2023). A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults. Vaccines. 11(6). 1091–1091. 1 indexed citations

Beaty, Shannon M., Yuanzhang Li, Mark A. Sanborn, et al.. (2023). Differential Genome Replication of a Unique Single-Amino-Acid Mutation in the Adenovirus-4 Component of the Live Oral Adenovirus Type 4 and Type 7 Vaccine. Vaccines. 11(7). 1144–1144. 1 indexed citations

Shabram, Paul, et al.. (2022). Development of Pediatric Dosage Preparation for CVD 103-HgR Live Oral Cholera Vaccine. American Journal of Tropical Medicine and Hygiene. 107(2). 388–392.

Shabram, Paul, et al.. (2021). CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe. Scientific Reports. 11(1). 13188–13188. 1 indexed citations

Vang, Lo, Christopher S. Morello, Jason Mendy, et al.. (2021). Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus. PLoS neglected tropical diseases. 15(3). e0009195–e0009195. 19 indexed citations

Maxfield, Lori F., Peter Abbink, Kathryn E. Stephenson, et al.. (2015). Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization. Clinical and Vaccine Immunology. 22(11). 1166–1175. 7 indexed citations

Shabram, Paul & J L Kolman. (2014). Evaluation of A549 as a New Vaccine Cell Substrate: Digging Deeper with Massively Parallel Sequencing. PDA Journal of Pharmaceutical Science and Technology. 68(6). 639–650. 1 indexed citations

10.

Shabram, Paul, et al.. (2004). Scalability of a Disposable Bioreactor from 25 L-500 L Run in Perfusion Mode with a CHO-Based Cell Line: A Tech Review. BioProcessing Journal. 3(4). 51–56. 18 indexed citations

11.

Lehmberg, Elisabeth, Paul Shabram, Thomas Schluep, et al.. (2003). Adenovirus Reference Materials: Determination of Particle Concentrations Obtained by Orthogonal, Physical-Chemical Methods. BioProcessing Journal. 2(3). 50–55. 3 indexed citations

12.

Demers, G W, Duane E. Johnson, Van Tsai, et al.. (2003). Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.. PubMed. 63(14). 4003–8. 20 indexed citations

13.

Rahman, Amena, Van Tsai, Shu Fen Wen, et al.. (2001). Specific Depletion of Human Anti-adenovirus Antibodies Facilitates Transduction in an in Vivo Model for Systemic Gene Therapy. Molecular Therapy. 3(5). 768–778. 41 indexed citations

14.

Ramachandra, Murali, Amena Rahman, Aihua Zou, et al.. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nature Biotechnology. 19(11). 1035–1041. 113 indexed citations

15.

Shabram, Paul & Estuardo Aguilar-Córdova. (2000). Multiplicity of Infection/Multiplicity of Confusion. Molecular Therapy. 2(5). 420–421. 34 indexed citations

16.

Atencio, Isabella, Murali Ramachandra, Paul Shabram, & G W Demers. (2000). Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines.. PubMed. 11(5). 247–53. 60 indexed citations

17.

Cheney, I. Wayne, Duane E. Johnson, Jenny B. Avanzini, et al.. (1998). Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.. PubMed. 58(11). 2331–4. 162 indexed citations

18.

Shabram, Paul, Richard J. Gregory, Mark Horn, et al.. (1997). Analytical Anion-Exchange HPLC of Recombinant Type-5 Adenoviral Particles. Human Gene Therapy. 8(4). 453–465. 164 indexed citations

19.

Nyberg-Hoffman, Cassandra, et al.. (1997). Sensitivity and reproducibility in adenoviral infectious titer determination. Nature Medicine. 3(7). 808–811. 170 indexed citations

20.

Huyghe, Bernard, Xiaodong Liu, Suganto Sutjipto, et al.. (1995). Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column Chromatography. Human Gene Therapy. 6(11). 1403–1416. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact